SEATTLE, WA–(Marketwired – Feb 28, 2017) – CFN Media Group (“CannabisFN”), the leading creative agency and digital media network dedicated to legal cannabis, announces publication of an article discussing the initiation of Tetra Bio-Pharma Inc.’s (OTC PINK: GRPOF) (CNSX: TBP) clinical trial in Canada and the company’s goals in the United States, especially in light of recent comments by the White House press secretary.
Tetra Bio-Pharma recently announced that the Therapeutic Products Directorate (“TPD”) of Health Canada approved its Phase I clinical study of PPP001 covering smoked cannabis for the management of uncontrolled pain in cancer and AIDS patients. The announcement was followed one week later by the beginning of the trial, as Tetra was clearly ready to get going. The trial is a first study approved that could eventually lead to approval of the product as a prescription drug. The study assesses single and 7-day multiple daily ascending doses